Changes in high molecular weight kininogen levels during and after cardiopulmonary bypass surgery measured using a chromogenic peptide substrate assay

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 6, 2002, Pages 561-568

  Gallimore, Mike J ^a   Jones, D W ^a   Winter, M ^a   Wendel, H P ^a  

^a KENT AND CANTERBURY HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid antibodies; Cardiopulmonary bypass; Chromogenic substrate assay; High molecular weight kininogen

Indexed keywords

4 NITROANILINE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; CALCIUM CHLORIDE; CHROMOGENIC SUBSTRATE; HIGH MOLECULAR WEIGHT KININOGEN; PHOSPHOLIPID ANTIBODY; PREKALLIKREIN; ACUTE PHASE PROTEIN; DIAGNOSTIC AGENT; PEPTIDE;

ADULT; ARTICLE; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOMETRY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; BLOOD; METABOLISM; MIDDLE AGED; REFERENCE VALUE; REPRODUCIBILITY; SPECTROSCOPY; STANDARD;

ACUTE-PHASE PROTEINS; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; CARDIOPULMONARY BYPASS; CHROMOGENIC COMPOUNDS; FACTOR XA; FACTOR XII; FEMALE; HUMANS; KININOGEN, HIGH-MOLECULAR-WEIGHT; MALE; MIDDLE AGED; PEPTIDES; REFERENCE STANDARDS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SPECTRUM ANALYSIS;

EID: 0036741307     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200209000-00012     Document Type: Article

References (31)

1. Jacobsen S. Separation of two different substrates for plasma kinin-forming enzymes. Nature 1966; 210: 98-99.
2. Saito H, Ratnoff OD, Waldmann R, Abraham JP. Fitzgerald trait: deficiency of a hitherto unrecognised agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis, generation of kinins and the property of diluted plasma enhancing vascular permeability (PF/DIL). J Clin Invest 1975; 55: 1082-1089.
3. Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes J, et al. Williams trait: human kininogen deficiency with deminished levels of plasminogen activator and prekallikrein associated with abnormalities of the Hageman factor dependent pathways. J Clin Invest 1975; 56: 1650-1662.
4. Wuepper KD, Miller DR, Lacombe MJ. Flaujeac trait: deficiency of human plasma kininogen. J Clin Invest 1975; 56: 1663-1672.
5. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-3843.
6. Colman RW. Biologic activities of the contact factors in vivo. Potentiation of hypotension, inflammation, and fibrinolysis and inhibition of cell adhesion, angiogenisis and thrombosis. Thromb Haemost 1999; 82: 1568-1577.
7. Schmaier AH. Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions. Curr Opin Hematol 2000; 7: 261-265.
8. Kleniewski J, Donaldson VH. Quantitation of human high molecular weight kininogen (HMW-KGN) by specific hemaglutination inhibition reaction. Proc Soc Exp Biol Med 1977; 156: 113-117.
9. Proud D, Pierce JV, Pisano JJ. Radioimmunoassay of human high molecular weight kininogen in normal and deficient plasmas. J Lab Clin Med 1980; 95: 563-574.
10. Bouma BN, Kerbiriou DM, Vlooswijk RAA, Griffin JH. Immunological studies of prekallikrein, kallikrein and high molecular weight kininogen in normal and deficient plasmas and in plasma after cold-dependent activation. J Lab Clin Med 1980; 96: 693-709.
11. Van Iwaarden F, de Groot PG, Sixma JJ, Berrettinini M, Bouma BN. High molecular weight kininogen is present in cultured human endothelial cells: localisation, isolation, and characterization. Blood 1988; 71: 1268-1276.
12. Lammle B, Zuraw BL, Heeb MJ, Schwarz HP, Berenettini M, Curd JG, Griffin JH. Detection and quantification of cleaved and uncleaved high molecular weight kininogen in human plasma. Thromb Haemost 1988; 59: 151-161.
13. Scott CF, Colman RW. Sensitive antigenic determinations of high molecular weight kininogen performed by covalent coupling of capture antibody. J Lab Clin Med 1992; 119: 77-86.
14. Scott CF, Shull B, Muller-Esterl W, Colman RW. Rapid direct determination of low and high molecular weight kininogen in human plasma by particle concentration fluorescence immunoassay (PCFIA). Thromb Haemost 1997; 77: 109-118.
15. Scott CF, Pixley RA, Colman RW. A new assay for high molecular weight kininogen in normal and deficient plasma using a chromogenic substrate. Thromb Res 1987; 48: 685-700.
16. Karlsrud TS, Buo L, Aasen AO, Johansen HT. Quantification of kininogens in plasma. A functional method based on the cysteine protease inhibitor activity. Thromb Res 1996; 82: 265-273.
17. Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis L, Curd J, Colman RW. Prekallikrein activation and high molecular weight kininogen consumption in hereditary angioedema. N Engl J Med 1983; 308: 1050-1054.
18. Karlsrud TS, Buo L, Aasen AO, Johansen HT. Cleavage of plasma high molecular weight kininogen in surgical ICU patients. Intensive Care Med 1996; 22: 760-765.
19. Saito H, Goldsmith G, Waldmann R. Fitzgerald factor (high molecular weight kininogen) clotting activity in human plasma in health and in disease and in various animal plasmas. Blood 1976; 48: 941-947.
20. Cugno M, Scott CF, Salerno F, Lorenzano E, Muller-Esterl W, Agostini A, Colman RW. Parallel reduction of plasma levels of high and low molecular weight kininogen in patients with cirrhosis. Thromb Haemost 1999; 82: 1428-1432.
21. Christie MP, Gattlen P, Fritschi J, Lammle B, Berger W, Marbet GA, Duckert F. The contact phase of blood coagulation in diabetes mellitus and in patients with vasculopathy. Thromb Haemost 1984; 52: 221-223.
22. Gallimore MJ, Jones DW, Winter M. Factor XII determinations in the presence and absence of phospholipid antibodies. Thromb Haemost 1998; 79: 87-90.
23. Jones DW, Gallimore MJ, Winter M. An automated chromogenic peptide substrate assay for coagulation factor XII. Blood Coagul Fibrinolysis 1998; 9: 183-187.
24. Gallimore MJ, Jones DW, Wendel HP. A chromogenic substrate assay kit for factor XII: evaluation and use for the measurement of factor XII in cardiopulmonary bypass patients. Thromb Res 1999; 94: 103-109.
25. Gallimore MJ, Friberger P. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein 'like' activity in human plasma. Thromb Res 1982; 25: 293-298.
26. Jones DW, Gallimore MJ, Winter M. Pseudo factor XII deficiency and phospholipid antibodies. Thromb Haemost 1996; 75: 696-697.
27. Halbmayer WM, Haushofer A, Angerer V, Fischer M. The discrimination of factor XII deficiency and lupus anticoagulant. Thromb Haemost 1996; 75: 698-699.
28. Dolan G, Kirby S, Vong ST, Horn EH, Westby JC. Interference of FXI: C measurement by antiphospholipid antibodies: a potential source of error in diagnosis of FXI deficiency [abstract]. Blood Coagul Fibrinolysis 1997; 8: 470.
29. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister H-E. Aprotinin in cadio-pulmonary bypass-effects on the Hageman factor (FXII) kallikrein system and blood loss. Blood Coagul Fibrinolysis 1992; 3: 99-104.
30. Wachtfogel YT, Harpel PC, Edmunds LH Jr, Colman RW. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor and plasmin-alpha 2-plasmin inhibitor complexes during cardiopulmonary bypass. Blood 1989; 73: 468-471.
31. Cugno M, Nussberger J, Biglioli P, Giovagnoni MG, Gardinali M, Agostini A. Cardiopulmonary bypass increases plasma bradykinin concentrations. Immunopharmacology 1999; 43: 145-147.